Luye Pharma (HKG:2186) secured Macao government's approval to market toludesvenlafaxine hydrochloride extended-release tablets, according to a Monday filing with the Hong Kong bourse.

The drug, branded Ruoxinlin, is indicated for major depressive disorder, the filing said.

Phase 3 study results showed the drug reduces anxiety, retardation, fatigue, and anhedonia or lack of interest, promotes social functions, and improves cognition, the filing said.